Comparative Pharmacology
Head-to-head clinical analysis: EUTHROID 2 versus EUTHROID 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTHROID 2 versus EUTHROID 3.
EUTHROID-2 vs EUTHROID-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
None Documented
None Documented
T4: 6-7 days (euthyroid); T3: approximately 1 day; clinical context: requires 6-8 weeks for steady state with T4 therapy.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Renal: ~20-40% of T4 and T3 metabolites; fecal: ~40-60% as conjugated metabolites; minor biliary elimination.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Category C
Category C
Thyroid Hormone Replacement
Thyroid Hormone Replacement